Journal of Diagnostics Concepts & Practice ›› 2024, Vol. 23 ›› Issue (04): 371-377.doi: 10.16150/j.1671-2870.2024.04.004
• Academic trend at home and abroad • Previous Articles Next Articles
Received:
2024-03-18
Accepted:
2024-05-13
Online:
2024-08-25
Published:
2024-08-25
Contact:
ZHENG Ying
E-mail:zhengying@fudan.edu.cn
CLC Number:
ZHANG Xin, ZHENG Ying. Interpretation of cancer death burden data from disease surveillance sites in China from 2005 to 2020[J]. Journal of Diagnostics Concepts & Practice, 2024, 23(04): 371-377.
Table 1
The changes in the average years of life lost due to cancer in China from 2005 to 2020
肿瘤 | 2020年 | 2005年 | 变化情况* | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
全部人群(年) | 男性(年) | 女性(年) | 全部人群(年) | 男性(年) | 女性(年) | 全部人群(年) | 男性(年) | 女性(年) | |||
全部肿瘤 | 23.60 | 23.78 | 23.27 | 27.34 | 27.78 | 26.50 | -3.74 | -4.00 | -3.23 | ||
白血病 | 37.35 | 36.28 | 38.81 | 50.71 | 49.55 | 52.25 | -13.36 | -13.27 | -13.44 | ||
脑神经癌 | 31.55 | 32.87 | 29.86 | 38.39 | 38.94 | 37.56 | -6.83 | -6.07 | -7.70 | ||
乳腺癌 | 30.81 | 18.64 | 30.96 | 32.57 | 26.88 | 32.65 | -1.75 | -8.24 | -1.69 | ||
子宫颈癌 | 30.30 | - | 30.30 | 31.66 | - | 31.66 | -1.36 | - | -1.36 | ||
卵巢癌 | 28.52 | - | 28.52 | 30.39 | - | 30.39 | -1.87 | - | -1.87 | ||
鼻咽癌 | 27.62 | 28.12 | 26.12 | 31.34 | 32.11 | 29.17 | -3.72 | -3.98 | -3.05 | ||
肝癌 | 27.12 | 28.47 | 23.14 | 30.64 | 32.04 | 26.64 | -3.52 | -3.57 | -3.50 | ||
其他肿瘤 | 26.65 | 26.95 | 26.32 | 30.90 | 30.53 | 31.24 | -4.24 | -3.58 | -4.92 | ||
淋巴癌 | 25.41 | 25.91 | 24.41 | 31.85 | 32.27 | 31.04 | -6.44 | -6.36 | -6.62 | ||
口腔癌 | 22.10 | 23.48 | 18.82 | 24.62 | 25.07 | 23.68 | -2.52 | -1.59 | -4.86 | ||
喉癌 | 21.99 | 22.67 | 17.46 | 24.83 | 25.74 | 21.14 | -2.84 | -3.06 | -3.69 | ||
肺癌 | 21.98 | 22.38 | 21.01 | 24.85 | 25.36 | 23.64 | -2.87 | -2.97 | -2.63 | ||
多发性骨髓瘤 | 21.75 | 21.79 | 21.68 | 26.54 | 26.22 | 27.13 | -4.79 | -4.43 | -5.44 | ||
胃癌 | 21.64 | 21.93 | 21.00 | 24.28 | 24.99 | 22.82 | -2.64 | -3.06 | -1.82 | ||
胰腺癌 | 21.57 | 22.05 | 20.77 | 23.32 | 23.85 | 22.43 | -1.75 | -1.80 | -1.66 | ||
结直肠癌 | 21.29 | 21.71 | 20.73 | 24.20 | 25.00 | 23.21 | -2.90 | -3.29 | -2.48 | ||
食管癌 | 20.87 | 22.10 | 17.13 | 23.65 | 24.89 | 20.67 | -2.78 | -2.79 | -3.54 | ||
肾癌 | 20.64 | 21.96 | 18.54 | 27.03 | 27.17 | 26.80 | -6.39 | -5.21 | -8.26 | ||
胆囊癌 | 19.65 | 20.47 | 18.90 | 21.38 | 22.23 | 20.64 | -1.73 | -1.76 | -1.74 | ||
甲状腺癌 | 18.79 | 19.78 | 18.15 | 21.28 | 23.08 | 20.11 | -2.49 | -3.30 | -1.96 | ||
皮肤癌 | 17.22 | 18.57 | 15.80 | 22.39 | 23.32 | 21.27 | -5.17 | -4.75 | -5.47 | ||
膀胱癌 | 16.58 | 16.89 | 15.25 | 19.67 | 19.97 | 18.69 | -3.09 | -3.07 | -3.44 | ||
前列腺癌 | 15.71 | 15.71 | - | 17.56 | 17.56 | - | -1.85 | -1.85 | - |
Table 2
Comparison of the top 10 cancer incidences in China and the United States in 2022
中国 | 美国 | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
发病率 顺位 | 肿瘤类型 | 发病率 (/10万) | 死亡率 (/10万) | 发病人 数顺位 | 死亡人 数顺位 | 肿瘤类型 | 发病率 (/10万) | 死亡率 (/10万) | 发病人 数顺位 | 死亡人 数顺位 | |
1 | 肺癌 | 40.8 | 26.7 | 1 | 1 | 乳腺癌 | 95.9 | 12.2 | 1 | 4 | |
2 | 乳腺癌 | 33.0 | 6.1 | 6 | 7 | 前列腺癌 | 75.2 | 8.1 | 2 | 5 | |
3 | 甲状腺癌 | 24.6 | 0.5 | 3 | 22 | 肺癌 | 31.9 | 16.6 | 3 | 1 | |
4 | 肝癌 | 20.1 | 8.6 | 4 | 2 | 结直肠癌 | 27.0 | 7.9 | 4 | 2 | |
5 | 子宫颈癌 | 15.0 | 12.6 | 8 | 9 | 子宫癌 | 22.5 | 3.1 | 9 | 15 | |
6 | 胃癌 | 13.8 | 4.5 | 5 | 3 | 黑素瘤 | 16.5 | 1 | 5 | 17 | |
7 | 前列腺癌 | 13.7 | 9.4 | 9 | 11 | 肾癌 | 12.8 | 1.9 | 8 | 12 | |
8 | 食管癌 | 9.7 | 3.3 | 7 | 5 | NHL | 12.5 | 2.6 | 7 | 8 | |
9 | 子宫癌 | 8.3 | 6.7 | 15 | 21 | 甲状腺癌 | 12.1 | 0.3 | 12 | 23 | |
10 | 卵巢癌 | 6.8 | 1.1 | 17 | 14 | 白血病 | 11.2 | 3.1 | 10 | 7 |
Table 3
Comparison of the top 10 cancer deaths between the National Cause of Death Monitoring System in 2020 and GLOBCAN 2022
发病率 顺位 | 肿瘤类型 | 2020年国家死因监测系统 | GLOBOCAN2022 | 变化情况* | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
死亡例数 (万) | 死亡率 (/10万) | 死亡例数 占比(%) | 肿瘤类型 | 死亡例数 (万) | 死亡率 (/10万) | 占肿瘤死亡 例数(%) | 死亡例数 (万) | 死亡率 (/10万) | 死亡例数 占比(%) | ||||
全部肿瘤 | 239.78 | 170.80 | 100.00 | 全部肿瘤 | 256.06 | 181.40 | 100.00 | 16.28 | 10.60 | 0.00 | |||
1 | 肺癌 | 76.61 | 54.57 | 32.00 | 肺癌 | 73.33 | 51.90 | 28.64 | -3.28 | -2.67 | -3.36 | ||
2 | 肝癌 | 36.77 | 26.19 | 15.30 | 肝癌 | 31.65 | 22.40 | 12.36 | -5.12 | -3.79 | -2.94 | ||
3 | 胃癌 | 29.12 | 20.74 | 12.10 | 胃癌 | 26.04 | 18.40 | 10.17 | -3.08 | -2.34 | -1.93 | ||
4 | 结直肠癌 | 18.24 | 13.00 | 7.60 | 结直肠癌 | 24.00 | 17.00 | 9.37 | 5.76 | 4.00 | 1.77 | ||
5 | 食管癌 | 17.33 | 12.34 | 7.20 | 食管癌 | 18.75 | 13.30 | 7.32 | 1.42 | 0.96 | 0.12 | ||
6 | 胰腺癌 | 10.04 | 7.15 | 4.20 | 胰腺癌 | 10.63 | 7.50 | 4.15 | 0.59 | 0.35 | -0.05 | ||
7 | 乳腺癌 | 5.71 | 4.06 | 2.40 | 乳腺癌 | 7.50 | 10.90 | 2.93 | 1.79 | 6.84 | 0.53 | ||
8 | 白血病 | 5.49 | 3.91 | 2.30 | 脑神经癌 | 5.66 | 4.00 | 2.21 | -0.48 | -0.31 | -0.34 | ||
9 | 脑神经癌 | 5.42 | 3.86 | 2.30 | 子宫颈癌 | 5.57 | 8.10 | 2.18 | 0.24 | 0.14 | -0.09 | ||
10 | 子宫颈癌 | 4.48 | 3.19 | 1.90 | 白血病 | 5.01 | 3.60 | 1.96 | 1.09 | 4.91 | 0.28 |
[1] | ZHENG R S, ZHANG S W, SUN K X, et al. Cancer statistics in China, 2016[J]. Zhonghua Zhong Liu Za Zhi, 2023, 45(3):212-220. |
[2] |
WEI W, ZENG H, ZHENG R, et al. Cancer registration in China and its role in cancer prevention and control[J]. Lancet Oncol, 2020, 21(7):e342-e349.
doi: 10.1016/S1470-2045(20)30073-5 pmid: 32615118 |
[3] | 徐睿锋, 孙鑫, 田雨, 等. 《2016年中国癌症发病死亡数据》要点解读[J]. 中国胸心血管外科临床杂志, 2024, 31(3):343-356. |
XU R F, SUN X, TIAN Y, et al. Interpretation of the key points of cancer incidence and mortality in China, 2016[J]. Chin Clin J Thorac Cardiovasc Surg, 2024, 31(3):343-356. | |
[4] |
QI J, LI M, WANG L, et al. National and subnational trends in cancer burden in China, 2005-20: an analysis of national mortality surveillance data[J]. Lancet Public Health, 2023, 8(12):e943-e955.
doi: 10.1016/S2468-2667(23)00211-6 pmid: 38000889 |
[5] | 郑弘, 周天枢. 平均减寿年数AYLL及与其它死因统计指标的比较[J]. 数理医药学杂志, 1998(4):42-43. |
ZHENG H, ZHOU T S. Average years of life lost AYLL and comparison with other statistical indicators of causes of death[J]. J Math Med Pharmacol, 1998(4):42-43. | |
[6] | 郝捷, 魏文强. 2021年中国肿瘤登记年报[M]. 北京: 人民卫生出版社, 2022:1-2. |
HAO J, WEI W Q. China Cancer Registry Annual Report, 2021[M]. Beijing: People's Medical Publishing House, 2022:1-2. | |
[7] | 全国肿瘤登记中心, 卫生部疾病预防控制局. 中国肿瘤登记年报[M]. 北京: 军事医学科学出版社, 2009 |
National Cancer Registry Center, Bureau of Disease Control and Prevention, Ministry of Health.[M]. Beijing: Military Medical Science Press, 2009. | |
[8] |
胡志强, 游伟程, 潘凯枫, 等. 中、美两国癌症流行特征分析——《2023美国癌症统计报告》解读[J]. 科技导报, 2023, 41(18):18-28.
doi: 10.3981/j.issn.1000-7857.2023.18.003 |
HU Z Q, YOU W C, PAN K F, et al. Epidemiological characteristics of cancers in China and America:Interpretation of the report of American cancer statistics, 2023[J]. Sci Technol Rev, 2023, 41(18):18-28. | |
[9] | 尹周一, 王梦圆, 游伟程, 等. 2022美国癌症统计报告解读及中美癌症流行情况对比[J]. 肿瘤综合治疗电子杂志, 2022, 8(2):54-63. |
YING Z Y, YOU W C, PAN K F, et al. Interpretation on the report of American cancer statistics, 2022 and comparison of cancer prevalence in China and America[J]. J Multidisciplinary Cancer Manage, 2022, 8(2):54-63. | |
[10] | LIU X, YU Y, WANG M, et al. The mortality of lung cancer attributable to smoking among adults in China and the United States during 1990-2017[J]. Cancer Commun (Lond), 2020, 40(11):611-619. |
[11] | SUN D, CAO M, LI H, et al. Cancer burden and trends in China: A review and comparison with Japan and South Korea[J]. Chin J Cancer Res, 2020, 32(2):129-139. |
[12] |
WANG M, LUO X, XU S, et al. Trends in smoking prevalence and implication for chronic diseases in China: serial national cross-sectional surveys from 2003 to 2013[J]. Lancet Respir Med, 2019, 7(1):35-45.
doi: 10.1016/S2213-2600(18)30432-6 pmid: 30482646 |
[13] | 马文月. 2012-2017年云南省蒙自市居民死因监测结果与疾病负担分析[D]. 兰州大学, 2019. |
MA W Y. Monitoring results of causes of death and analysis of disease burden in Mengzi City, Yunnan Province from 2012 to 2017[D]. Lanzhou University, 2019. | |
[14] | LIU S, WU X, LOPEZ A D, et al. An integrated national mortality surveillance system for death registration and mortality surveillance, China[J]. Bull World Health Organ, 2016, 94(1):46-57. |
[15] | ZHENG R S, CHEN R, HAN B F, et al. Cancer incidence and mortality in China, 2022[J]. Zhonghua Zhong Liu Za Zhi, 2024, 46(3):221-231. |
[16] | 中国疾病预防控制中心慢性非传染性疾病预防控制中心, 国家卫生健康委统计信息中心. 中国死因监测数据集2020[M]. 北京: 中国科学技术出版社, 2021. |
China Center for Chronic Noncommunicable Disease Control and Prevention, National Center for Statistics and Information of Health Commission. China cause-of-death surveillance data set 2020[M]. Beijing: Science and Technology Press of China, 2021. | |
[17] | 郭晓娟, 田国祥, 李燕, 等. GLOBOCAN数据库架构介绍及数据分析方法[J]. 中国循证心血管医学杂志, 2020, 12(7):775-777. |
GUO X J, TIAN G X, LI Y, et al. GLOBOCAN database architecture introduction and data analysis method[J]. Chin J Evid-Based Cardiovasc Med, 2020, 12(7):775-777. | |
[18] | 曹毛毛, 陈万青. GLOBOCAN 2020全球癌症统计数据解读[J]. 中国医学前沿杂志(电子版), 2021, 13 (3): 63-69. |
CAO M M, CHEN W Q. Interpretation on the global cancer statistics of GLOBOCAN 2020[J]. Chin J Front Med (Electron ed), 2021, 13(3):63-69. | |
[19] | 郑莹, 周昌明. 综合防治,抗击癌症的必由之路——美国癌症数据的启示[J]. 中华结直肠疾病电子杂志, 2018, 7(2):102-108. |
ZHEN Y, ZHOU C M. Comprehensive strategies, the route leading to cancer prevention and control---What we learned from US Cancer Statistics[J]. Chin J Colorectal Dis, 2018, 7(2):102-108. |
[1] | ZHANG Zhiping, CAI Shilong, GENG Yanlong, LIU Shiyou. Analysis of incidence trend of thyroid cancer in Baoshan District, Shanghai from 2000 to 2022 [J]. Journal of Diagnostics Concepts & Practice, 2024, 23(04): 378-384. |
[2] | FU Xina, XU Xin, LI Tianjie, JIN Ying. Study on the risk factors for persistent infection of high-risk human papillomavirus after cervical conization [J]. Journal of Diagnostics Concepts & Practice, 2024, 23(04): 416-423. |
[3] | LIU Juan, YIN Lijuan, FAN Desheng. The clinicopathologic significance of AR, SKP2, SOX10, PD-L1 and TILs expression in triple-negative breast cancer [J]. Journal of Diagnostics Concepts & Practice, 2024, 23(02): 162-172. |
[4] | OU Dan, CAI Gang, CHEN Jiayi. Bioinformatics analysis for expression of RAD51AP1 in triple negative breast cancer with brain metastasis [J]. Journal of Diagnostics Concepts & Practice, 2024, 23(02): 146-154. |
[5] | HUANG Rui, RAO Huiying. Current status, screening and diagnostic strategies for hepatitis C virus infection in the context of “elimination” [J]. Journal of Diagnostics Concepts & Practice, 2024, 23(01): 1-8. |
[6] | DING Jingfeng, AO Weiqun, ZHU Zhen, SUN Jing, XU Lianggen, ZHENG Shibao, YU Jingjing, HU Jinwen. The value of radiomics based on T2WI and DWI of MRI in preoperative prediction of extramural vascular invasion in rectal cancer [J]. Journal of Diagnostics Concepts & Practice, 2024, 23(01): 46-56. |
[7] | ZHANG Ying, JIANG Xiaofei. Analysis of global burden of bacterial infections: an interpretation of Global mortality associated with 33 bacterial pathogens in 2019 [J]. Journal of Diagnostics Concepts & Practice, 2023, 22(06): 541-549. |
[8] | ZHAN Dui, NIMA Zhuoma, DOU Ji, PINGCUO Zhuoma, QI Jinlei. Analysis of all-cause mortality data of residents in Shannan City, Tibet, 2021 [J]. Journal of Diagnostics Concepts & Practice, 2023, 22(06): 562-566. |
[9] | NI Zhongxin, CHEN Hui. Study on the diagnostic efficacy of ADNEX model in differentiating metastatic and primary ovarian cancer [J]. Journal of Diagnostics Concepts & Practice, 2023, 22(06): 573-578. |
[10] | ZHOU Yilei, ZHANG Miao, GUO Rui, ZHOU Jinxin, LI Biao, LI Xiang. Value of 18F-PSMA PET/MRI for early diagnosis of recurrence and metastasis in prostate cancer patients after radical prostatectomy [J]. Journal of Diagnostics Concepts & Practice, 2023, 22(06): 567-572. |
[11] | QIN Xiaodan, SUN Huiling, PAN Bei, PAN Yuqin, WANG Shukui. miR-1229-3p inhibits the malignant progression of colorectal cancer and serves as a potential biomarker [J]. Journal of Diagnostics Concepts & Practice, 2023, 22(05): 429-440. |
[12] | FAN Zhenjia, ZHAO Juntao, ZHOU Jiakuan, LI Zhanquan, WAN Yinglei. Application value of ST2 combined with CEA and CYFRA211 in diagnosis of early non-small cell lung cancer [J]. Journal of Diagnostics Concepts & Practice, 2023, 22(05): 441-447. |
[13] | DAI Jingyi, JIANG Jingting. Advances in tumour markers for diagnosis of hepatocellular carcinoma [J]. Journal of Diagnostics Concepts & Practice, 2023, 22(05): 486-493. |
[14] | LIU Yifei. DNA methylation detection assists early screening and diagnosis of tumors [J]. Journal of Diagnostics Concepts & Practice, 2023, 22(04): 393-401. |
[15] | DING Yongjie, ZHANG Liu, LI Qingyun. New knowledge of prophylaxis and treatment about cancer-associated thrombosis [J]. Journal of Diagnostics Concepts & Practice, 2023, 22(04): 323-331. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||